PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031 Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no personant of 1995, no personant

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

SHEET 1 of 1

COMPL	ETE IF KNOWN		
Application Number	10/773,971		
Confirmation Number			
Filing Date	February 6, 2004		
First Named Inventor	John Patrick Goodall, et al.		
Group Art Unit			
Examiner Name			
Attorney Docket Number	9520		

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	U.S. PATENT DO Number	OCUMENT Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US 3,368,522	Α	Cordis	02-13-1968	
		US 3,756,483	Α	Schraeder	09-04-1973	
٠		US 3,843,034	Α	Lewandowsky	10-22-1974	
		US 4,638,921	A	Sigl et al.	01-27-1987	· ·
,		US 6,273,359	B1	Newman et al.	08-14-2001	
. ,		US 6,382,552	B1	Paul et al.	05-07-2002	

FOREIGN PATENT DOCUMENTS

EXAMINER	Cite		REIGN PATENT D		Name of Patentee or	Date of Publication of	Pages, Columns, Lines Where	
INITIALS*	No. ¹	Office ³	Number⁴	Kind Code⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	T ⁶
		wo	00/65973	A1	Kimberly-Clark	11-09-2000		
	-	wo	00/65975	A1	Kimberly-Clark	11-09-2000		
		WO	01/76436	A1	Kimberly-Clark	10-18-2001		
	<u> </u>	WO	01/76438	A1	Kimberly-Clark	10-18-2001		
	(WO	01/76439	A1	Kimberly-Clark	10-18-2001		
	ζ	wo	01/76440	A1	Kimberly-Clark	10-18-2001	-	
	(_wo_	01/82765	A1	Kimberly-Clark	11-08-2001		
	(wo	01/89937	A2	P&G	11-29-2001		
		WO	02/21988	A1	Kimberly-Clark	03-21-2002		
		,wo	02/32281	A1	Kimberly-Clark	04-25-2002	·-	
	~	wo	02/41742	A1	Kimberly-Clark	05-30-2002		
	7	wo	02/43546	A1	P&G	06-06-2002		
	-	wo	02/43547	A1	Kimberly-Clark	06-06-2002		


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INIȚIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
EXAMINER		DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.



P&G Case 9520

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

John Patrick Goodall, et al. : Confirmation No.
Serial No.: 10/773,971 : Group Art Unit

Filed: February 6, 2004 : Examiner

For: Kit For Providing Wound Web Materials And Method For Marketing The Materials

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [X] 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.



2. [] 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. [] 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. [] Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[] (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the
cited documents are enclosed.
OR
[X](2) (For use with applications filed after June 30, 2003.) In accordance with 3'
C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non
patent literature.
OR
[] (3) All of the cited references were previously cited by or submitted to the USPTO in
prior application Case No, U.S. Patent Application Serial No, filed Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.
OR
[] (4) Copies of all said documents, except Cite Numbers, were submitted
and considered in parent application U.S. Patent Application Serial No, filed, applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.
[] (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.
[] (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.
Additional information is attached.

Respectfully submitted,

FOR: JOHN PATRICK GOODALL, ET AL.

By.

Attorney for Applicant(s) Registration No. 48,683

(513) 634-7419

(IDS.doc) (Last Revised 10/10/03)